🔥Telegram İfşa

More evidence for the value of cdk4/6 inhibitor in 1L patients with triple positive (ER+/HER2+) breast cancer. -ORR 61% with a non chemo containing regimen -mPFS 30 months

Very important Insight at #ASCO25 >10% of ER -/low breast cancer patients had increased ER expression in residual tumors post-NAC ✅Retesting can unlock adjuvant endocrine therapy. ⬇️Don’t skip it if there’s residual disease! meetings.asco.org/abstracts-pres… #Oncology OncoAlert ASCO

Toxicity with this regimen is high. And I don’t mean hyperglycemia. I mean stomatitis. It works well if you can stay on it, but that’s a big if. #ASCO25 #bcsm

Dr Sonya Reid makes excellent point in Metastatic TNBC Sadly 50% of patients do not make it to second line therapy in mTNBC. In that case, waiting beyond first line to give a more effective regimen seems silly. #bcsm #ASCO25

.NRG Oncology BR003 shows adding carboplatin to weekly paclitaxel following DD AC for adj tx of node-positive or high-risk node-negative TNBC did NOT result in a statistically significant improvement in IDFS #ASCO25 OncoAlert

📌 The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/ HER2- breast cancer. ✨Erica L. Mayer, MD, MPH, FASCO ✔️Rapid Oral Abstract Session Breast Cancer-Local/Regional/ Adjuvant OncoAlert #OncoAlertAF #ASCO25 #Day3

Dr. Frank Sinicrope presents ATOMIC, chemo +/- atezolizumab as adjuvant tx for Stage III dMMR colon cancer. 54% of patients high risk (T4/N2). 3-year DFS 86.4 vs 76.6%, HR 0.50 (P<0.0001) Alliance for Clinical Trials in Oncology #ASCO25

Atezo arm with doubling of G4 neuropathy (14 vs 7%) and more patient deaths. Do these patients need oxaliplatin? #ASCO25

Dr. Chalabi proposes that lower risk tumors get treated with surgery, chemo/IO per ATOMIC and higher risk tumors consider neoadjuvant IO per NICHE-2. #ASCO25

1st Plenary #ASCO25: #ATOMIC Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50), benefit seen in all subgroups. DFS 100% in Niche2 - ⬆️ discontinuation w/ Atezo - OS not mature - ⬆️ Gr4 neutropenia - To Adj or to NeoAdj?

Key Takeaways from Dr. DeMichele #ASCO25

Tremendous discussion of the SERENA-6 trial by Angie DeMichele, MD, MSCE, FASCO. Outstanding results, though not ready for clinical practice (yet). Important to take into account financial, psychological & systemic costs of the strategy. Make sure to review this presentation if you missed it.

This is what I’ll take away from #ASCO25. And two additional points: 1. It received a standing ovation 2. Did not have to say overall survival data hadn’t matured … in contrast to the plenary session’s abstracts. It should have been included!

Presented at #ASCO25: In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results:

A practice changing trial that IMMEDIATELY needs to be challenged. 2L TDXd only 10%, adj SOC was less than usual, and given PATINA 44mos, a stop-TDXd switch to CDK4/5 + H(P) needs to be explored for QOL. We should not minimize the 48% Fatigue, incld ~8% G3 #ASCO25 OncoAlert

Slide updated! ✔️ Looking forward to the presentation here at #ASCO25 ASCO

Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. ASCO #ASCO25 OncoAlert

📌 Do We "Node" What to Do About the Axilla❓ Great discussion👏🏻 ✨Mediget Teshome, MD, FACS, MPH OncoAlert #OncoAlertAF #ASCO25

SOFT/TEXT 15 year update #ASCO25 2/2

A nice review on Postmastectomy RT and RNI in the era of de-escalation of treatment #bcsm doi.org/10.1200/OP-25-… Erika Hamilton, MD, FASCO @DrAGraff Sara Tolaney Hope Rugo Matteo Lambertini, MD PhD Jame Abraham, MD, FACP Dr Sarah Sammons Kristina Jankovic, MD Antonio Giordano, MD PhD Harold J. Burstein, MD, PhD, FASCO Nancy Lin, MD Giampaolo Bianchini Rebecca Shatsky, MD